The Pharma Data
JUNE 18, 2021
June 8, 2021 /PRNewswire/ — Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), is changing the way BOTOX ® Cosmetic, the #1 selling neurotoxin treatment 1 , is connecting with consumers. “BOTOX ® Cosmetic is honoring and celebrating the dynamic people who use our products. IRVINE, Calif.
The Pharma Data
MARCH 30, 2021
2] – The atogepant application demonstrates AbbVie’s longstanding commitment to providing multiple migraine treatment options, including BOTOX® (onabotulinumtoxinA), a preventive treatment for those with chronic migraine, and UBRELVY® (ubrogepant), an acute treatment for adults with migraine. IMPORTANT SAFETY INFORMATION.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MARCH 18, 2022
Complaints upheld by the Prescription Medicines Code of Practice Authority (PMCPA) include two against AZ and Allergan – now part of AbbVie – related to promotion of medicines on social media sites, including LinkedIn.
Roots Analysis
JANUARY 29, 2024
Medical Aesthetics is an area of modern medicine that specializes in improving the outer appearance of an individual without surgery. In fact, medical aesthetics companies are also investigating the effects of “Baby Botox” given in lower concentrations to provide more subtle results. It is worth noting that in 2022, more than 7.4
pharmaphorum
NOVEMBER 18, 2020
The decision means that with two CGRP antibodies now cleared for migraine prevention, the first drug in the class to be approved in Europe – Novartis’ Aimovig (erenumab) – has fallen further behind its rivals in getting access to the UK market.
The Pharma Data
NOVEMBER 2, 2020
Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids THC and CBD and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols and triglycerides, according to company data.
pharmaphorum
NOVEMBER 18, 2020
The decision means that with two CGRP antibodies now cleared for migraine prevention, the first drug in the class to be approved in Europe – Novartis’ Aimovig (erenumab) – has fallen further behind its rivals in getting access to the UK market.
Expert insights. Personalized for you.
52 
Let's personalize your content